Is Arbutus Biopharma Corp (ABUS) a Buy, Sell, or Hold?
Arbutus Biopharma Corp
NASDAQ:ABUS
$4.61 USD
-$0.06 (-1.18%)
- Volume
- 1.69M
- Average Volume
- 2.15M
- Market Capitalization
- $910.65M
- P/E Ratio
- 5.53
- Dividend Yield
- 0.00%
- Price Target
- $8.50
- Year High
- $5.38
- Year Low
- $3.08
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $54.26
| Source | Headline |
|---|---|
|
Arbutus Biopharma: Moderna Validates My IP Bull Case
Arbutus Biopharma is now much better capitalized after Moderna validated the value of its LNP patents. As for ABUS' in-house assets, I think Imdusiran has shown durable viral control. The main caveat is that it comes from combo therapies. Their balance sheet gives them a comfortable runway to pursue imdusiran's upcoming Phase 2b trial, which is yet another optionality vertical for the stock. seekingalpha.com - 2026-07-13 08:00:00 |
|
Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna globenewswire.com - 2026-05-13 07:30:00 |
|
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran WARMINSTER, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for imdusiran for the treatment of chronic hepatitis B (“cHBV”). globenewswire.com - 2026-04-15 07:30:00 |
